← Leaderboards
Alda Tufro
University Of Virginia Charlottesville
$7,351,512
Attributed
$7,351,512
Total exposure
5
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $611.2K · FY2005–20$1M$750K$500K$250K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$7,351,512 · 5
By mechanism
R01$7,109,052 · 4
K08$242,460 · 1
Top collaborators
No co-investigators on record.
Most similar at University Of Virginia Charlottesville
Same institution · by research overlap
- Helmy M Siragy$13,726,344
- Sarah J Parsons$11,850,077
- Ian G Macara$23,928,271
- Shu Man Fu$19,462,975
- Raymond E Keller$5,850,117
Others in their field
Top investigators on “Kidney”
- Jeffrey P Krischer · University Of South Florida$540,222,210
- John M Lachin · George Washington University$155,894,464
- David M Nathan · Massachusetts Institute Of Technology$127,229,266
- Kathryn Hirst · Caritas St. Elizabeth'S Medical Center$111,521,899
- David Heimbrook · Leidos Biomedical Research, Inc.$83,221,586
- Peter Scott Heeger · Case Western Reserve University$80,562,246
Research focus
KidneyVascular Endothelial Growth FactorsAngiogenesisFoot ProcessBaseProteinuriaRenal Glomerular DiseaseMolecularSignal TransductionPhenotypeIn VitroPodocyteActinsEnd Stage Renal FailureDefectLaboratory MousePathogenesisKidney FailureEnzyme Linked Immunosorbent AssayNephrinRegulationDiabetic NephropathyAdultPathway Interactions
Grant awards (25)
Molecular characterization of a novel cause of human FSGS$490,056
R01 · FY2020 · DK · contact PI
Molecular characterization of a novel cause of human FSGS$484,026
R01 · FY2019 · DK · contact PI
Molecular characterization of a novel cause of human FSGS$490,056
R01 · FY2018 · DK · contact PI
Molecular characterization of a novel cause of human FSGS$555,633
R01 · FY2017 · DK · contact PI
Function of semaphorin3a in diabetic nephropathy$249,750
R01 · FY2016 · DK · contact PI
Function of semaphorin3a in diabetic nephropathy$249,750
R01 · FY2015 · DK · contact PI
Function of semaphorin3a in diabetic nephropathy$249,750
R01 · FY2014 · DK · contact PI
Function of semaphorin3a in diabetic nephropathy$249,750
R01 · FY2013 · DK · contact PI
Functions of VEGF-A in podocytes:implications for renal disease$334,648
R01 · FY2011 · DK · contact PI
Functions of VEGF-A in podocytes:implications for renal disease$348,169
R01 · FY2010 · DK · contact PI
Functions of VEGF-A in podocytes:implications for renal disease$351,016
R01 · FY2009 · DK · contact PI
Functions of VEGF-A in podocytes:implications for renal disease$222,756
R01 · FY2008 · DK · contact PI
Functions of VEGF-A in podocytes:implications for renal disease$129,322
R01 · FY2008 · DK · contact PI
Kidney vascularization: semaphorin-mediated mechanisms.$287,013
R01 · FY2006 · DK · contact PI
Kidney Vascularization-- VEGF-mediated Mechanisms$317,300
R01 · FY2005 · DK
Kidney vascularization: semaphorin-mediated mechanisms.$293,920
R01 · FY2005 · DK
Kidney Vascularization-- VEGF-mediated Mechanisms$317,300
R01 · FY2004 · DK
Kidney vascularization: semaphorin-mediated mechanisms.$293,920
R01 · FY2004 · DK
Kidney Vascularization-- VEGF-mediated Mechanisms$317,300
R01 · FY2003 · DK
Kidney vascularization: semaphorin-mediated mechanisms.$296,059
R01 · FY2003 · DK
Kidney vascularization: semaphorin-mediated mechanisms.$25,379
R01 · FY2003 · DK
Kidney Vascularization-- VEGF-mediated Mechanisms$281,200
R01 · FY2002 · DK
Kidney Vascularization-- VEGF-mediated Mechanisms$274,979
R01 · FY2001 · DK
VEGF AND NEPHROVASCULAR DEVELOPMENT$121,230
K08 · FY2001 · DK
VEGF AND NEPHROVASCULAR DEVELOPMENT$121,230
K08 · FY2000 · DK